Company Profiles

driven by the PitchBook Platform

T-cell

T-cell
2010 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Series A LATEST DEAL TYPE
$1.86M LATEST DEAL AMOUNT
3 INVESTORS
Description

Developer of novel T-cell-based therapies designed to develop products for kidney transplantation. The company's T-cell-based therapies prevents overreactions in the immune system thereby treating the side effects that often surpass the costs of the post-transplantation immunosuppression therapy itself, enabling patients to supersede chronic immunosuppression and their adverse effects.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Services
Other Industries
Biotechnology
Primary Office
  • Jägerallee 37i
  • 14471 Potsdam
  • Germany

+49 0331 00000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore T-cell’s full profile, request a free trial.

T-cell Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 15-May-2012 $1.86M 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

T-cell Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Constantin Bastian Leander Venture Capital Venture Capital Minority 000 0000 000000 0
High-Tech Gründerfonds Venture Capital Minority 000 0000 000000 0
Investitionsbank des Landes Brandenburg Venture Capital Minority 000 0000 000000 0

T-cell Executive Team (4)

Name Title Board
Seat
Contact
Info
Christian Inderthal Chief Executive Officer
Hans-Deiter Volk Chief Scientific Advisor
Petra Reinke Chief Clinical Advisor

1 Former Executive

You’re viewing 3 of 4 executives. Get the full list »